Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Depression and Suicide in the ED
NCT04266288Phase 4Completed
- Sponsor
- MercyOne Des Moines Medical Center
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and suicidal ideation comparing Ketamine with Placebo (2 arms). Primary endpoints: Depression Symptom Response at 4 hours and Emergency Department Return Visit at 30 days. Started Oct 2019; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT04266288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04266288.